Superpower Prescription Process: A Women's Health Review of the Preventive Lab + Rx Platform

What Is Superpower and How Does Its Prescription Process Work?

Superpower is a preventive-health telehealth company that sells a subscription combining broad-panel blood testing with access to clinician-reviewed prescriptions for medications that overlap with the longevity and optimization space. You complete an online intake form, get a lab order, visit a phlebotomy site, and then receive a clinician review followed by a treatment plan that may include prescription medications.

The intake form covers lifestyle factors, symptoms, and health goals. It is not a diagnostic interview with a live clinician before your labs, which matters for women because hormonal context, such as cycle day, recent pregnancy, or perimenopausal status, can significantly shift how labs are interpreted. Follicle-stimulating hormone (FSH) alone can vary threefold across a single menstrual cycle, so a snapshot value without cycle-day documentation may be clinically misleading.

The Intake Form and Lab Order Step

After payment, you fill out a digital intake questionnaire. The depth of hormonal history collected here matters enormously for women. Platforms that do not ask about cycle regularity, last menstrual period, contraceptive use, or perimenopausal symptoms risk drawing labs at hormonally noisy time points and then treating the result as if it were a steady-state value.

The Lab Draw

Superpower uses major national phlebotomy networks, which is convenient. However, for women who need cycle-timed draws, such as a mid-luteal progesterone on day 21 or an early-follicular FSH on day 3, a generic lab order that does not specify timing can produce numbers that look abnormal but are physiologically normal, or vice versa. ACOG guidance emphasizes individualized screening intervals and clinical context for every lab value, which is difficult to achieve through a purely asynchronous model.

Clinician Review and Prescription

A clinician reviews your results asynchronously and, if appropriate, issues prescriptions through a pharmacy partner. The prescriptions are mailed or sent electronically. You do not necessarily speak with the clinician before receiving a prescription. For low-risk supplements this may be acceptable. For medications such as rapamycin or metformin, a conversation about your reproductive plans, contraceptive status, and menstrual health is not optional; it is part of responsible prescribing.

What Does Superpower Prescribe? A Women's-Health Assessment of Each Drug Class

Superpower's prescribable list includes metformin, low-dose naltrexone (LDN), rapamycin (sirolimus), thyroid medications, peptides such as BPC-157, and select sex hormones. Each carries distinct considerations for women at different life stages.

Metformin

Metformin is the most evidence-backed drug on this list for women. It is first-line for type 2 diabetes and is commonly used off-label in PCOS. A 2020 meta-analysis in Fertility and Sterility found metformin improved menstrual regularity and reduced androgen levels in women with PCOS, making it one of the few longevity-adjacent drugs with direct female-specific trial data.

For women trying to conceive, metformin is generally continued through the first trimester in PCOS and is classified as FDA pregnancy category B with substantial human safety data. It does transfer into breast milk at low levels; the Academy of Breastfeeding Medicine considers it compatible with lactation. If Superpower prescribes metformin for longevity rather than for a diagnosed condition, you should discuss whether the dose and monitoring schedule match your hormonal and reproductive context.

Rapamycin (Sirolimus)

Rapamycin is the drug that most distinguishes Superpower from conventional telehealth. It is an mTOR inhibitor approved for organ-transplant rejection and certain cancers, used here off-label for its theorized anti-aging effects at low intermittent doses. The evidence for longevity benefit in healthy humans is preliminary; the most cited work comes from animal studies and small observational series, not randomized controlled trials in women.

Rapamycin is contraindicated in pregnancy. The FDA label for sirolimus assigns it to pregnancy category C, and animal reproductive studies show embryo-fetal toxicity. Any woman of reproductive potential prescribed rapamycin needs reliable contraception for the duration of use and a washout period before attempting conception. This is not a footnote. It belongs in the first conversation a prescriber has with a woman of reproductive age.

Rapamycin also transfers into breast milk in animal models. Human lactation data are absent. Women who are breastfeeding should not take it.

Regarding female-specific pharmacokinetics: women generally have higher peak blood concentrations of immunosuppressant drugs at equivalent weight-based doses due to differences in body composition and CYP3A4 activity, though sirolimus-specific sex-stratified PK data in healthy adults are sparse, a gap that warrants disclosure.

Low-Dose Naltrexone (LDN)

LDN at 1.5-4.5 mg nightly is used off-label for autoimmune conditions, fibromyalgia, and mood symptoms. Women are disproportionately affected by the autoimmune conditions for which LDN is most studied, including Hashimoto's thyroiditis and multiple sclerosis. A small randomized trial in Crohn's disease (Clin Gastroenterol Hepatol 2011) showed benefit, but large female-specific trials are lacking.

LDN blocks opioid receptors. If you use opioid-based pain medication, including for endometriosis or postoperative gynecologic pain, LDN will precipitate withdrawal. This interaction requires explicit screening.

Pregnancy: naltrexone is FDA category C. It is not recommended in pregnancy, and no safe dose is established in lactation. Women trying to conceive should discontinue LDN and discuss timing with a clinician.

Thyroid Medications

Thyroid prescriptions through Superpower may include levothyroxine or combinations with liothyronine. This is a particularly high-stakes area for women. Women are 5 to 8 times more likely than men to develop hypothyroidism, and thyroid requirements shift substantially during perimenopause and pregnancy.

ATA and ACOG guidelines both specify that TSH targets differ by trimester in pregnancy: the first-trimester upper limit is 2.5 mIU/L, not the standard 4.5 mIU/L. If Superpower issues a thyroid prescription without asking about pregnancy status or plans, the dose may be subtherapeutic at the moment it matters most.

Postpartum thyroiditis affects approximately 5-10% of women in the year after delivery, often producing a transient hyperthyroid phase followed by hypothyroidism. An asynchronous platform that does not account for postpartum status could both over- and under-treat these women.

Peptides (BPC-157, TB-500, Others)

Peptides are not FDA-approved drugs. They exist in a regulatory grey zone, and the FDA has issued guidance restricting compounding pharmacies from producing certain peptides due to insufficient safety data. The longevity use case for most peptides rests on animal studies and anecdotal reports. There are essentially no randomized controlled trial data in women.

For women who are pregnant, breastfeeding, or trying to conceive, the correct answer on any unapproved peptide is avoidance. No human reproductive safety data exist.

Superpower's Lab Panel: What It Measures and What It Misses for Women

The following framework compares what a women's-health-optimized preventive panel should include versus what a generic longevity panel typically covers. This comparison was developed by the WomanRx editorial board for use across platform reviews.

Standard longevity panel (typically included):

• Complete metabolic panel
• Lipid panel
• CBC
• HbA1c and fasting glucose
• hsCRP
• TSH
• Testosterone (total)
• DHEA-S
• IGF-1
• Vitamin D

Women's-health additions that a sex-informed panel should include:

| Lab | Why It Matters for Women | Cycle-Timing Needed? | |---|---|---| | Estradiol (E2) | Perimenopause staging, PCOS, bone health | Yes, day 3 or mid-cycle | | FSH | Ovarian reserve screening, menopause status | Yes, day 3 | | LH | PCOS ratio, ovulation confirmation | Yes | | Progesterone | Luteal phase adequacy, cycle health | Yes, day 21-22 | | Free testosterone + SHBG | PCOS, HSDD, androgen excess | Less critical | | Anti-Mullerian Hormone (AMH) | Ovarian reserve, PCOS, fertility planning | No | | Prolactin | Irregular cycles, galactorrhea, pituitary | Fasting, morning | | DHEA-S | Adrenal androgen excess | No | | Iron, ferritin | Heavy menstrual bleeding, fatigue in premenopausal women | No | | TPO antibodies | Hashimoto's in women with thyroid symptoms | No |

A panel that omits estradiol, LH, FSH timing guidance, ferritin, and cycle documentation is not a women's preventive panel. It is a unisex panel applied to a woman.

ACOG's well-woman visit guidance explicitly ties screening recommendations to life stage. A 28-year-old woman with irregular periods needs different labs than a 52-year-old woman in perimenopause, even if their TSH is identical.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know Before Starting Superpower

This section is required for any platform that prescribes medications, and the information below applies to the specific drugs Superpower offers.

Rapamycin: Contraindicated in pregnancy. Requires reliable contraception throughout use. No lactation data; avoid while breastfeeding.

Metformin: Generally compatible with pregnancy in PCOS context (category B). Compatible with breastfeeding at low infant exposure levels. Discuss with your OB before continuing in the first trimester if not being prescribed for a specific indication.

Low-dose naltrexone: Category C. Not recommended in pregnancy or lactation. Discontinue before attempting conception.

Thyroid medications (levothyroxine): Safe in pregnancy when dosed correctly. TSH targets change by trimester. Dose typically increases 25-30% in the first trimester. Must be monitored every 4-6 weeks during pregnancy per ATA/ACOG guidelines.

Peptides (compounded): No human reproductive safety data. Avoid in pregnancy, while trying to conceive, and during lactation.

The platform gap: A telehealth platform that does not screen explicitly for pregnancy status, breastfeeding status, and contraception use before issuing any of these prescriptions falls below the standard of care for women of reproductive age. Before accepting any Superpower prescription, confirm with the prescribing clinician whether you have disclosed your full reproductive history, current contraception method, and any pregnancy plans.

Who This Platform Is and Is Not Right For, by Life Stage

Reproductive Years (Ages 18-40, Not Trying to Conceive)

Superpower's metformin and thyroid offerings may be appropriate if you have a documented indication such as insulin resistance or confirmed hypothyroidism. The platform is less appropriate as a first-line option if your primary symptoms are menstrual irregularity, acne, hair loss, or fatigue without a clear diagnosis, because those symptoms require a differential that a brief asynchronous intake does not reliably provide. PCOS affects 6-12% of women of reproductive age and is frequently missed or misclassified.

Trying to Conceive or Peripregnancy

Rapamycin, LDN, and unapproved peptides are not compatible with attempting pregnancy. Metformin and thyroid medications require active monitoring in pregnancy that Superpower's asynchronous model does not provide. This is not the right platform for your primary care during pregnancy planning.

Perimenopause (Typically Ages 45-55)

The metabolic shifts of perimenopause, including declining estradiol, rising FSH, insulin resistance, and altered lipid profiles, are real and under-addressed in conventional medicine. The Menopause Society (formerly NAMS) affirms that hormone therapy initiated within 10 years of menopause or before age 60 has a favorable benefit-risk profile for most women, yet Superpower does not appear to have a dedicated perimenopause protocol. If the platform prescribes testosterone or DHEA for this group, the absence of estradiol monitoring and endometrial safety consideration is a significant gap.

Post-Menopause

Bone health, cardiovascular risk, and GSM (genitourinary syndrome of menopause) are the dominant preventive targets in post-menopause. A longevity-focused lab panel that does not include a bone density referral trigger, DEXA screening, or vaginal estrogen assessment is incomplete for this life stage. USPSTF recommends DEXA for all women 65 and older, and earlier for women with risk factors.

Is Superpower Legit? What the Evidence Actually Says

Superpower is a licensed telehealth operation with real clinicians reviewing labs and issuing prescriptions through compliant pharmacy channels. That part is legitimate. The harder question is whether the clinical model is appropriately calibrated for women.

Several concerns warrant transparency:

Asynchronous prescribing of high-risk drugs. Rapamycin prescribed without a live conversation about contraception and reproductive plans does not meet the standard most women's health societies would set. ACOG's position on telehealth explicitly notes that the standard of care does not change simply because a visit is virtual.

Off-label drug use without strong trial data in women. The AGCT longevity trial (Targeting Aging with Metformin, TAME) is the largest ongoing longevity trial using metformin; it is actively enrolling and has not yet reported primary outcomes. Rapamycin's human longevity evidence comes largely from the ITP mouse studies and a small number of human observational reports. Women have been historically under-represented in longevity pharmacology trials, meaning extrapolation from male-dominated datasets is routine, not exceptional.

No documented sex-specific dosing adjustment. Women typically have lower lean body mass, different adipose distribution, and distinct CYP450 activity profiles compared to men. A 2020 analysis in Biology of Sex Differences documented that women experience adverse drug reactions at higher rates than men partly due to weight-unadjusted dosing. A platform that does not address this in its clinical protocol is behind current pharmacology standards.

What Superpower does well: Access is genuinely broadened. The lab bundling reduces the common problem of insurers declining preventive panels that are not tied to a diagnosis code. For a healthy woman with no active conditions who wants a broad metabolic baseline and is not pregnant or trying to conceive, the cost may compare favorably to out-of-pocket cash-pay labs. The convenience of a single dashboard for results is real.

Superpower vs. Alternatives for Women

Several platforms compete in this space, and the comparison below focuses on factors that matter specifically for women.

| Platform | Hormone Panel | Cycle-Timed Labs | Perimenopause Protocol | Pregnancy Screening | Monthly Cost (approx.) | |---|---|---|---|---|---| | Superpower | Partial | Not documented | Not documented | Not documented | ~$99 | | Midi Health | Yes (core offering) | Clinician-guided | Yes, dedicated | Yes | Varies by insurance/cash | | Allara (PCOS) | Yes | Yes | Limited | Yes | ~$99+visits | | Parsley Health | Yes | Clinician-guided | Yes | Yes | ~$150+visits | | Wisp | Partial | No | Limited | Partial | Per visit |

This table is based on publicly documented clinical offerings as of mid-2025. Protocols change; confirm current offerings directly with each platform before making a decision.

How Much Does Superpower Cost?

Superpower's subscription is reported at approximately $99 per month, which bundles lab draws and clinician review. Prescription costs are separate and depend on the medication and pharmacy. Compounded medications, including rapamycin and peptides, are not covered by insurance and can add $50-300 or more per month depending on dose and formulation.

For women, the full cost comparison should include what the platform does not provide: a pelvic exam, cervical cancer screening, mammography referral, bone density evaluation, or contraception management. These require a separate provider. A $99/month longevity subscription does not replace a gynecology relationship.